Is Vivus Management Delaying Its Inevitable Demise?

Vivus has had a tough time launching obesity drug Qysmia, and shares have taken a beating, losing nearly half of their value over the past year. This has caused some activist investors, led by hedge fund First Manhattan, to call for a change in leadership, including looking to replace the drugmaker's CEO and nine directors. 

In this video, health-care analyst David Williamson discusses Vivus' surprise decision to push back the shareholder meeting from Monday to Thursday, First Manhattan's aggressive response, and what the outcome could mean for investors in Vivus and its obesity-drug rival.

Can Vivus pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on Vivus and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and Vivus -- complete with a full year of free updates -- today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 17, 2013, at 8:15 AM, shirtbrigade wrote:

    I do think the EU approval for Spedra and their partnering there, added some loft to the stock. Scrip sales improving for Q, thats part of it too. FMC looks like they have essentially succeeded, so its hard to tell which is more propellant...!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2540818, ~/Articles/ArticleHandler.aspx, 8/29/2014 6:07:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement